Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Open Access
- 18 December 2023
- Vol. 79 (5) , 1258-1270
Abstract
Background: This is the first report on the effects of abrocitinib, a Janus kinase 1–selective inhibitor, on the expression of skin biomarkers in patients with moderate‐to‐severe atopic dermatitis (AD).Methods: JADE MOA (NCT03915496) was a double‐blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once‐daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 weeks. The primary endpoint was change from baseline in markers of inflammation (matrix metalloproteinase [MMP]‐12), epidermal hyperplasia (keratin‐16 [KRT16]), T‐helper 2 (Th2) immune response (C‐C motif chemokine ligand [CCL]17, CCL18, and CCL26), and Th22 immune response (S100 calcium binding protein A8, A9, and A12 [S100A8, S100A9, and S100A12]) in skin through 12 weeks.Results: A total of 46 patients received abrocitinib 200 mg (n = 14), abrocitinib 100 mg (n = 16), or placebo (n = 16). Abrocitinib improved AD clinical signs and reduced itch. Gene expression of MMP‐12, KRT16, S100A8, S100A9, and S100A12 was significantly decreased from baseline with abrocitinib 200 mg (at Weeks 2, 4, and 12) and abrocitinib 100 mg (at Weeks 4 and 12) in a dose‐dependent manner. Abrocitinib 200 mg resulted in significant decreases from baseline in CCL17 expression at Week 12 and CCL18 expression at Weeks 2, 4, and 12; no significant decreases were observed for CCL26.Conclusions: Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate‐to‐severe AD.Keywords
Funding Information
- Pfizer
This publication has 44 references indexed in Scilit:
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapiesJournal of Allergy and Clinical Immunology, 2017
- Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitisExperimental Dermatology, 2016
- Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and PathwaysPLOS ONE, 2015
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Therapeutic opportunities of the IL-22–IL-22R1 systemNature Reviews Drug Discovery, 2013
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- IL-17 and IL-22: siblings, not twinsTrends in Immunology, 2010
- Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasisJournal of Allergy and Clinical Immunology, 2007
- CCL18 Is Expressed in Atopic Dermatitis and Mediates Skin Homing of Human Memory T CellsThe Journal of Immunology, 2005
- A Th2 Chemokine, TARC, Produced by Keratinocytes May Recruit CLA+CCR4+ Lymphocytes into Lesional Atopic Dermatitis SkinJournal of Investigative Dermatology, 2000